-

Dompé Foundation Doubles Its Funding for Rita Levi Montalcini Fellowships in Neuroscience and Neurobiology

MA, Ph.D and post-doc candidates at US universities to be supported with 1 million USD
Applications on www.dompefoundation.org | Deadline December 31st, 2023

WASHINGTON--(BUSINESS WIRE)--The Dompé Foundation has announced it doubled to 1 million dollars its support to MA, PhD and post-doc candidates from United States-based universities for 2023. This funding opportunity, which honors the legacy of the only female Italian Nobel laureate in Medicine, is intended for students of any nationality that have already been admitted to a MA, PhD or post-doc program in Neuroscience and Neurobiology at a US university. As with former grants, the Foundation will offer scholarships and fellowships to the most promising candidates. Applications will soon be online on the Foundation’s website. Deadline is December 31st, 2023.

The fellows of previous editions will be gathering to meet Sergio Dompé, Executive President of Dompé farmaceutici and members of the Board on June 20, 2023 at the Public Library in Washington D.C. for the Embrace the Challenge in Science roundtable and will be available to the press for interviews. The US fellows present in Washington D.C. on June 20 are attending graduate programs at Stanford University, Georgetown University, Washington University in St. Louis, and Johns Hopkins University.
The Rita Levi Montalcini Scholarships and Fellowships are part of a more extensive program to support the higher education of young talents in STEM fields, which has seen the Dompé Foundation award over 70 scholarships and invest more than 6 million euros in the last 3 years (half of which for 2023/24 fellows).

Established in 2020 by Sergio Dompé, the Foundation aims to break down the barriers to higher education for promising students with a low income while contributing to the development of the careers of the future, especially within the Life Sciences industry. The degree programs sponsored by the Foundation provide students with a multidisciplinary education, a strong grounding in new technologies and innovation principles, and the opportunity to access an international network: these ingredients are key for those who intend to be at the forefront of innovation and research today.

To-date, the Dompé Foundation has involved 21 top universities in US and Europe: Stanford University, Georgetown University, Washington University in St. Louis, University of Pittsburgh, Harvard Medical School, Johns Hopkins University, University of Chicago, Yale, and Weill Cornell Medicine in the US; Queen Mary University of London, Bocconi University, and other universities in Italy. The Foundation’s commitment to the progress of scientific knowledge is part of Dompé farmaceutici’s long lasting investments in R&D and innovative startups.

Contacts

Media contacts
Guido Romeo | Head Corporate Communications | Dompé farmaceutici
Mob. +39 349 4154010 | guido.romeo@dompe.com

Dompé Foundation



Contacts

Media contacts
Guido Romeo | Head Corporate Communications | Dompé farmaceutici
Mob. +39 349 4154010 | guido.romeo@dompe.com

Social Media Profiles
More News From Dompé Foundation

From the Eye to the Brain: World’s Top Scientists Gather in Rome to Discuss Future of Neurotrophins in Eye and Brain Research

ROME--(BUSINESS WIRE)--Nature Conferences has convened a meeting of leading global scientists to discuss the state of the art and future lines of research on neurotrophins. The event, From the Eye to the Brain, will focus on the potential new applications of neurotrophins in therapeutic areas including ophthalmology and the central nervous system. The program takes place in Rome June 11-12 and is sponsored by Dompé farmaceutici. Neurotrophins were discovered by Italian Nobel laureate Dr. Rita L...

Dompé farmaceutici Appoints Shannon K. Sullivan as Chief Commercial Officer Biotech

MILAN, Italy & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé, a leading biopharmaceutical company with operations in Italy and the US, appointed Shannon K. Sullivan as Chief Commercial Officer (CCO)....

New Data Reveal Role of SARS-Cov-2 Spike Protein in Covid-19 Associated Coagulopathy

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COV...
Back to Newsroom